TREATING TB IN CHILDREN

All children treated for TB should be registered with the National TB programme.

The following dosages of first-line anti-TB medicines should be used daily for the treatment of TB in children:

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isoniazid (H)</td>
<td>10 mg/kg (range 7–15 mg/kg)</td>
</tr>
<tr>
<td>Rifampicin (R)</td>
<td>15 mg/kg (range 10–20 mg/kg)</td>
</tr>
<tr>
<td>Pyrazinamide (Z)</td>
<td>35 mg/kg (range 30–40 mg/kg)</td>
</tr>
<tr>
<td>Ethambutol (E)</td>
<td>20 mg/kg (range 15–25 mg/kg)</td>
</tr>
</tbody>
</table>

As children approach a body weight of 25 kg, adult dosages can be used.

- First line treatment of drug-sensitive TB consists of a two-month intensive phase with isoniazid, rifampicin, pyrazinamide (and, depending on the setting and type of disease, ethambutol), followed by a continuation phase with isoniazid and rifampicin for at least four months.
- HIV-infected children with TB require antiretroviral therapy (ART) and co-trimoxazole preventive therapy (CPT) in addition to TB treatment.
- Isoniazid in the same dosage is recommended as preventive therapy over six months for children under the age of five as well as HIV-positive children of any age.
- The support of the child, his/her parents and immediate family is vital to ensure the completion of treatment and a successful outcome. This may include nutritional, financial and counselling assistance.

NEW HOPE FOR CHILDREN WITH TB

SIMPLE, CHILD-FRIENDLY TB TREATMENT NOW AVAILABLE

Until recently, there was no appropriate first-line TB treatment designed for children. However, after sustained advocacy and new investment, now child-friendly formulations that do not need to be cut or crushed to achieve an appropriate dose are available, offering the opportunity to simplify and improve treatment for children everywhere.

The formulations were developed in line with the revised dosing published in the 2014 WHO Guidance on childhood TB through a project led by TB Alliance and WHO (Essential Medicines and Health Products department and the Global TB Programme), and funded by UNITAID and USAID.

The fixed-dose combinations (FDCs) are not new drugs, but rather improved formulations of currently used medicines recommended for the first line treatment of TB.

The FDCs are recommended to replace previously used medicines for children weighing less than 25 kg.

BENEFITS OF CHILD-FRIENDLY TB FORMULATIONS

- The right medicines in the right doses will increase adherence and save more lives. This is an important step in improving treatment and child survival from TB, and slowing the spread of drug-resistant TB.
- Simple TB medicines for children eases the TB burden on healthcare systems. Using fixed-dose combinations for children eases procurement of TB medicines. Fewer pills will simplify ordering and storage, and facilitate scale-up of pediatric treatment.
- Child-friendly medicines improve the daily lives of children and their families struggling with TB. Six months is a long time to take medicine. But the availability of treatment that tastes good and is simple to provide will ease the daily struggles of children, parents, and caregivers alike.
ABOUT THE FIXED-DOSE COMBINATIONS FOR CHILDREN

The formulations now available are:
For the intensive phase of TB treatment:
Rifampicin 75 mg + Isoniazid 50 mg + Pyrazinamide 150mg

For the continuation phase of TB treatment:
Rifampicin 75mg + Isoniazid 50 mg

The following dosing table provides information on the number of daily tablets needed to reach the proper dosing, based on the child’s weight:

<table>
<thead>
<tr>
<th>Weight band</th>
<th>Intensive phase: RHZ 75/50/150*</th>
<th>Continuation phase: RH 75/50</th>
</tr>
</thead>
<tbody>
<tr>
<td>4-7 kg</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>8-11 kg</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>12-15 kg</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>16-24 kg</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>25+ kg</td>
<td>Adult dosages recommended</td>
<td></td>
</tr>
</tbody>
</table>

*Ethambutol should be added in the intensive phase for children with extensive disease or living in settings where the prevalence of HIV or of isoniazid resistance is high

HOW CAN COUNTRIES ACCESS THE NEW FORMULATIONS

Following approval by a WHO Expert Review Panel in June 2015, countries can access the new formulations through the Global TB Drug Facility (GDF).

TB high burden countries can utilize the WHO Collaborative Procedure for fast track registration and can benefit from technical assistance for transitioning from the old to the new formulations.

OTHER PRODUCTS IN THE PIPELINE

Other products under development and likely to be available in 2016 are:
- 100 mg ethambutol dispersible tablets;
- 100 mg isoniazid dispersible tablets (recommended for preventive therapy).

KEY REFERENCES


For more information:
TB Alliance [www.tballiance.org/children](http://www.tballiance.org/children)

©World Health Organization December 2016